KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Shares Outstanding for 16 consecutive years, with $117.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding fell 4.35% to $117.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $117.8 million through Dec 2025, down 4.35% year-over-year, with the annual reading at $117.8 million for FY2025, 4.35% down from the prior year.
  • Shares Outstanding for Q4 2025 was $117.8 million at Halozyme Therapeutics, roughly flat from $117.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $143.4 million in Q1 2021, with the low at $117.5 million in Q3 2025.
  • Average Shares Outstanding over 5 years is $130.6 million, with a median of $131.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding rose 5.92% in 2021, then dropped 7.6% in 2025.
  • Over 5 years, Shares Outstanding stood at $137.5 million in 2021, then dropped by 1.7% to $135.2 million in 2022, then decreased by 6.2% to $126.8 million in 2023, then decreased by 2.87% to $123.1 million in 2024, then decreased by 4.35% to $117.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $117.8 million, $117.5 million, and $117.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.